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Reduced nuclear factor erythroid 2-related factor 2 (NRF2) pathway activity was reported in models of chronic kidney disease
(CKD). Pharmacological activation of NRF2 is supposed to improve renal function, but data concerning the NRF2 activity in
human CKD are lacking. We investigated the NRF2 target NAD(P)H:quinone oxidoreductase 1 (NQO1) as a readout parameter
for NRF2 activity in monocytes of CKD patients (n = 63) compared to those of healthy controls (n = 16). The NQO1 gene
expression was quantiﬁed using real-time PCR and the protein content by in-cell Western assays. We found a 3-4-fold increase
in NQO1 gene expression in CKD 1–5 (n = 29; 3.5 for NQO1/ribosomal protein L41; p < 0 001). This was accompanied by a
1.1-fold increase in NQO1 protein (p = 0 06). Cardiovascular disease prevalence was higher in CKD 1–5 patients with higher
compared to those with lower NQO1 gene expression (p = 0 02). In advanced uremia, in dialysis patients (n = 34), NQO1
gene expression was less robustly upregulated than that in CKD 1–5, while NQO1 protein was not upregulated. We conclude
that in mononuclear cells of CKD patients, the NRF2 pathway is activated by coexisting pathogenic mechanisms, but in
advanced uremia, the eﬀectiveness of this upregulation is reduced. Both processes could interfere with pharmacological
NRF2 activation.
1. Introduction
The transcription factor NRF2 is a master transcriptional
regulator of cellular response to oxidative and electrophilic
stress. It activates a multitude of cellular defense processes
through induction of its target genes, including drug-
metabolizing and antioxidant enzyme genes [1]. Oxidative
or electrophilic stress can activate the NRF2 pathway by
an interaction with the cytoplasmic complex between
Kelch-like ECH-associated protein 1 (KEAP1) and NRF2.
As a result, NRF2 can escape ubiquitination and proteasomal
degradation, accumulate, and translocate to the nucleus. It
forms heterodimers with small Maf proteins, binds to anti-
oxidant/electrophilic response elements, and thereby ﬁnally
induces target gene expression [1, 2].
Cytosolic NQO1 is a conserved target gene of NRF2 and
can serve to monitor the activity of the NRF2 pathway [2].
During its clinical development, the NRF2 activator bardox-
olone methyl was investigated in a phase 1 clinical trial, in
patients with advanced malignancies. In this trial, the
NQO1 gene expression levels in peripheral blood mononu-
clear cells (PBMCs) were shown to be indicative of NRF2
pathway activation by the substance [3].
In animal models of renal diseases, impaired activity of
the NRF2 pathway and downregulation of the NQO1 gene
expression are major ﬁndings, both in renal and in nonre-
nal cells [2, 4, 5]. Furthermore, it was shown in animal
models that activation of the NRF2 pathway and increased
gene transcription, including those of NQO1, attenuated
kidney injury [6–8]. Therefore, there is a strong interest
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in the therapeutic potential of NRF2 activators in kidney
disease [9]. A phase 2b clinical trial with the NRF2 activator
bardoxolone methyl in CKD stages 3b and 4 demonstrated
an improvement in estimated glomerular ﬁltration rate
(eGFR) but suggested adverse eﬀects, for example, on liver
tissue [10]. A phase 3 clinical trial in CKD stage 4 patients
(BEACON) with the same substance also showed an
increased eGFR but had to be terminated because of a
higher rate of cardiovascular events in the treatment group
[11]. Currently, one more phase 2 clinical trial with bar-
doxolone methyl in CKD patients is recruiting participants
(NCT02316821). In the publication of the so far largest
clinical trial of bardoxolone methyl, the authors refer to
the impairment of NRF2 activity-dependent gene tran-
scription that was reported in animal models of CKD as
one rational for the clinical application of the substance
in CKD [11]. Accordingly, in our study, we investigated
the gene expression of NQO1 as a parameter of NRF2-
dependent gene transcription in human CKD. We present
a systematic analysis of this drug target on the level of
gene expression and protein content in CKD patients with
and without renal replacement therapy. The BEACON
trial was terminated because of a higher rate of cardiovas-
cular events in the intervention group [11]. A post hoc
analysis by the manufacturer of the substance identiﬁed
prior hospitalization for heart failure as a risk factor for heart
failure experienced during bardoxolone treatment [12].
Therefore, we investigated a relation between theNQO1 gene
expression as a measure for NRF2 pathway activity and car-
diovascular disease (CVD) prevalence in patients with non-
dialysis-dependent CKD.
Since systemic NRF2 activators target the NRF2 path-
way systemically and nonrenal adverse events were
reported, both nonrenal and renal cells of CKD patients
require investigation.
We therefore quantiﬁed the NQO1 gene expression as
a readout parameter for NRF2 pathway activity in mono-
cytes of patients with CKD with and without dialysis ther-
apy and compared it to those of healthy control subjects.
In parallel, NQO1 protein content was quantiﬁed in cells
of the same subjects.
2. Subjects and Methods
2.1. Study Subjects.We prospectively enrolled 63 consecutive
patients with CKD from the outpatient clinics of the Depart-
ment of Nephrology, Odense University Hospital, and 16
healthy control subjects. Among the group of CKD patients,
34 were undergoing dialysis therapy (hemodialysis, n = 33;
peritoneal dialysis, n = 1). The study was approved by the
regional ethics committee and written informed consent
was obtained. Hemodialysis patients were dialyzed with bio-
compatible membranes, three times per week, for 4-4.5
hours. Healthy control subjects were free from chronic or
acute disease. Study participants were 30 years or older.
CKD patients had veriﬁed CKD according to the 2012
Clinical Practice Guideline for the Evaluation and Manage-
ment of Chronic Kidney Disease, and patients with dialysis
therapy had been in dialysis treatment for at least 3 months
[13]. Exclusion criteria included pregnancy or breastfeeding,
acute illness leading to hospital admission, and functioning
renal allograft.
2.2. Collection of Clinical Data and Blood Samples. Clinical
data were obtained by physical examination, medical history
taking, and electronic medical records. This included the
record of age, sex, height, weight, smoking status, medical
history, and use of medications. Venous blood samples were
drawn in the morning from study participants. Samples from
hemodialysis patients were obtained before the start of
hemodialysis sessions. Plasma and serum were separated
and stored at −80°C. The eGFR was calculated using the
2009 CKD-EPI creatinine equation, and CKD stages were
determined based on eGFR categories according to the
KDIGO 2012 guideline [13].
2.3. Isolation of Circulating Monocytes. We isolated PBMCs
by density gradient centrifugation (Histopaque-1077,
Sigma-Aldrich, Denmark). Monocytes then were isolated
from PBMCs using anti-CD14-coated superparamagnetic
polystyrene beads (Fisher Scientiﬁc, Denmark) according to
the manufacturer’s protocol.
2.4. RNA Isolation, Reverse Transcription, and Quantitative
Real-Time PCR (RT-qPCR). Total RNA was isolated from
monocytes using an RNeasy Mini kit (Qiagen, Denmark)
according to the protocol described by the manufacturer.
cDNA was synthesized from 200ng of total RNA by reverse
transcription using a Transcriptor First-Strand cDNA Syn-
thesis Kit (Roche, Denmark). The ampliﬁcation of genes
was performed by quantitative real-time PCR using SYBR
Green (FastStart Essential DNA Green Master, Roche,
Denmark). The PCR conditions using a LightCycler96
Instrument (Roche, Denmark) were as follows: 95°C for
600 s and 50 cycles of 95°C for 10 s, 64°C (for NQO1, beta-
actin (ACTB), and ribosomal protein L41 (RPL41)) or 60°C
(for TATA-box binding protein (TBP)) for 10 s, and 72°C
for 10 s. The primers used were in Table 1.
To ensure a high reliability of the gene expression
results in our study, we tested a group of available refer-
ence genes in the cellular material of our study. We then
employed the “NormFinder” algorithm (http://moma.dk/
normﬁnder-software; [14]). The reference genes with the
highest expression stability in our sample material were
RPL41, ACTB, and TBP with stability values (SE) of 0.12
(0.06), 0.18 (0.06), and 0.22 (0.05), respectively. We there-
fore used these three genes for the relative quantiﬁcation
ofNQO1 gene expression. The ratio was calculated as follows:
ratio = 2(Cq reference gene)/2(Cq NQO1).
PCR products were size-fractionated on agarose gels for
product length control.
In the PCRs, water controls, no-template controls, and
no-RT controls were included. A melting curve analysis was
performed for each sample to ensure product homogeneity.
All measurements were performed in duplicate.
2.5. SDS-PAGE and Western Blotting. Protein was extracted
from monocytes using an extraction reagent for mammalian
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cells including a protease inhibitor cocktail (cOmplete
Lysis-M, pH7.6, Roche, Denmark). Proteins were separated
by 10% sodium-dodecyl-sulfate polyacrylamide gel electro-
phoresis (10% RunBlue SDS gel, Expedeon, UK) at 120V
for 45 minutes and transferred to polyvinylidendiﬂuoride
membranes at 100V for 75 minutes (Immun-Blot LF PVDF,
Bio-Rad, USA). Membranes were blocked with blocking
buﬀer (Superblock, Thermo Fisher Scientiﬁc, USA) for 1
hour at room temperature and incubated with the primary
antibodies rabbit anti-human NQO1 (ab34173, Abcam,
UK) or rabbit anti-human ACTB (sc-130656, Santa Cruz
Biotechnology, Germany). After washing with tris(hydrox-
ymethyl)aminomethane-buﬀered saline, the membranes
were incubated with the ﬂuorescence-labeled secondary
antibody F(ab′)2-goat anti-rabbit IgG (H+L) Alexa Fluor
488 (Fisher Scientiﬁc, Denmark). Imaging was performed
using a Carestream Imager 4000pro (Fisher Scientiﬁc,
Denmark) at 535 nm emission with an excitation wave-
length of 470nm.
2.6. Quantitative In-Cell Western Assay. To quantify the
NQO1 protein content in circulating monocytes, in-cell
Western assays were performed as recently described by
our group [15, 16]. For that purpose, monocytes were ﬁxed
with formaldehyde and permeabilized using Triton X-100
in 96-well plates. Cells were blocked using 1% bovine serum
albumin overnight at 4°C, then incubated with the primary
antibodies rabbit anti-human NQO1 (ab34173, Abcam,
UK) or rabbit anti-human ACTB (sc-130656, Santa Cruz
Biotechnology, Germany). After washing, cells were incu-
bated with the ﬂuorescence-labeled secondary antibody
F(ab′)2-goat anti-rabbit IgG (H+L) Alexa Fluor 488 (Fisher
Scientiﬁc, Denmark). All measurements were performed in
triplicate, and the NQO1 protein content was analyzed rel-
ative to the ACTB protein content as an internal reference.
Imaging was performed using an EnSpire Multimode Plate
Reader (PerkinElmer, Denmark) at 520 nm emission with
an excitation wavelength of 490nm.
3. Statistics
Continuous variables are given as median and interquartile
range, and categorical variables are given as counts and per-
centages. Groups were compared using Kruskal-Wallis test
with Dunn’s posttest or Mann–Whitney test. Diﬀerences in
categorical variables between groups were analyzed by Χ2
test (GraphPad prism software, version 5.0, GraphPad
Software, San Diego, CA). All statistical tests were two-
sided and a two-sided value of p < 0 05 was considered
statistically signiﬁcant.
4. Results
Population characteristics of study subjects are shown in
Table 2.
The NQO1 gene expression was signiﬁcantly higher in
monocytes from patients with CKD 1–5 (Kruskal-Wallis,
p = 0 004 for NQO1/ACTB; p < 0 001 for NQO1/RPL41; and
p < 0 001 for NQO1/TBP; Figures 1(a) and 1 (b)). Compared
to healthy controls, patients with CKD 1–5 showed a 3-4-fold
increase in the NQO1 gene expression (3.1 for NQO1/ACTB,
3.5 for NQO1/RPL41, and 4.2 for NQO1/TBP). In CKD 5
patients undergoing dialysis therapy (CKD 5D), median
NQO1 gene expression was numerically higher than that in
healthy controls but this was signiﬁcant only for the NQO1/
TBP ratio (a 2.6-fold increase for NQO1/TBP, p < 0 05,
Figure 1(b)). The relation between theNQO1 gene expression
level and CKD stage followed approximately a bell shape.
This is shown in the Supplementary Figure 1 available online
at https://doi.org/10.1155/2017/9091879 representing the
distribution of the NQO1 gene expression at the diﬀerent
CKD stages including advanced CKD with hemodialysis
therapy (Kruskal-Wallis, p = 0 005).
We also quantiﬁed the NQO1 protein content in cells of
the identical blood samples used for the gene expression
analyses described above. First, we proved that in the cell
material used for our study, the antibodies eﬀectively detected
NQO1 and ACTB proteins. Immunoblot analyses showed
staining of protein bands at the expected sizes (Figure 2(a)).
Figure 2(b) shows a representative example of an in-cell
Western assay used for the relative quantiﬁcation of the
NQO1 protein content in monocytes. Measurements were
performed in triplicate for each subject. Figure 2(c) depicts
the summary data for all in-cell Western analyses. The
NOQ1 protein content showed a 1.1-fold increase in CKD
1–5 patients compared to healthy controls (Mann–Whitney,
p = 0 06). In CKD 5D, the NQO1 protein content was not
diﬀerent from control subjects (Mann–Whitney, p = 0 72).
Furthermore, since cardiovascular events led to the
early termination of a large NRF2 activator trial in
Table 1
Name of gene product
Forward primer
Expected PCR product length (bp)
Reverse primer
NQO1
NM_000903.2
5′-CTGCCATCATGCCTGACTAA-3′
5′-TGCAGATGTACGGTGTGGAT-3′ 216
ACTB
NM_001101.3
5′-GGACTTCGAGCAAGAGATGG-3′
5′-AGCACTGTGTTGGCGTACAG-3′ 234
RPL41
NM_021104.1
5′-AAGATGAGGCAGAGGTCC-3′
5′-TCCAGAATGTCACAGGTCCA-3′ 248
TBP
NM_003194.4
5′-TGCACAGGAGCCAAGAGTGAA-3′
5′-CACATCACAGCTCCCCACCA-3′ 132
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non-hemodialysis-dependent CKD, we investigated the
prevalence of CVD in our study. For the analysis of the
NQO1 expression and prevalence of CVD in non-
hemodialysis-dependent CKD stages 1–5, we grouped the
patients according to their NQO1 gene expression below
or above the median and compared the frequency of
CVD between them. When we analyzed the overall preva-
lence of CVD (myocardial infarction/coronary artery dis-
ease, heart failure, cerebrovascular disease, and peripheral
artery disease), it was 2 out of 14 in the patient group
below median gene expression whereas in the group above
median NQO1 gene expression, the prevalence of CVD
was 8 out of 14 (Χ2 test, p = 0 02). The only common
underlying single disease type in our patient group was
cardiac insuﬃciency (1 out of 14 in the below median
group versus 7 out of 14 in the above median group; Χ2
test, p = 0 18).
5. Discussion
This study showed for mononuclear cells of CKD patients (i)
increased gene expression of the NRF2 target NQO1 in CKD
1–5, (ii) compared to CKD 1–5 a less robust increase in the
NQO1 gene expression in CKD 5D, (iii) slightly increased
NQO1 protein content in CKD 1–5, and (iv) higher preva-
lence of CVD among CKD 1–5 patients with a higher
NQO1 gene expression.
In our study, we investigated monocytes from periph-
eral blood of CKD patients. The monocyte-macrophage
lineage is of special importance in CKD. On the one hand,
they are involved in kidney injury and ﬁbrosis [17, 18].
On the other hand, monocytes and monocyte-derived
macrophages are involved in the pathogenesis of athero-
sclerosis and vascular disease in CKD [19–22]. The latter
is important with respect to our ﬁnding of higher CVD
Table 2: Clinical and demographical population characteristics.
Healthy (n = 16) CKD 1–5 (n = 29) CKD 5D (n = 34)
Age, years 38 (33–48) 68 (58–77) 67 (55–76)
Men, n (%) 9 (56) 19 (66) 23 (68)
BMI, kg/m2 24 (22–26) 30 (24–37)a 24 (22–28)b
Smoking, n (%) 2 (13) 3 (10) 6 (18)
Kidney disease, underlying cause, n (%) None
Glomerulonephritis 8 (28) 5 (15)
Hypertensive nephropathy 3 (10) 5 (15)
Interstitial nephritis 2 (7) 4 (12)
Diabetic nephropathy 1 (3) 2 (6)
Hereditary kidney disease 1 (3) 2 (6)
Other/unknown 14 (48) 16 (47)
Comorbidities, n (%) None
Hypertension 28 (97) 26 (76)
Diabetes 8 (28) 8 (24)
CVD
Myocardial infarction, coronary artery disease 6 (21) 10 (29)
Heart failure 8 (28) 16 (47)
Cerebrovascular disease 4 (14) 6 (18)
Peripheral artery disease 1 (3) 9 (26)
Medications None
AT receptor antagonist, ACE inhibitor 22 (76) 16 (47)
Beta blocker 9 (31) 15 (44)
Calcium channel inhibitors 13 (45) 9 (26)
Platelet aggregation inhibitor 6 (21) 6 (18)
Diuretic 19 (66) 11 (32)
Erythropoietin analog 6 (21) 29 (85)
Coumarin derivatives 5 (17) 6 (18)
eGFR, mL/min/1.73m2 n.d. 28 (17–43) n.a.
Time on dialysis, months n.a. n.a. 22 (11–49)
CRP, mg/L n.d. 5.3 (2.3–10.8)c 3.0 (1.4–10.5)d
Albumin, g/L n.d. 38 (35–41)e 38 (36–40)
Values are given as median (25%–75% percentile) or number (percentage). BMI: body mass index; AT: angiotensin; ACE: angiotensin converting enzyme; CRP:
C-reactive protein; n.d.: not done; n.a.: not applicable. an = 27; bn = 33; cn = 28; dn = 33; en = 28.
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prevalence in CKD patients with an NQO1 gene expres-
sion above the median in monocytes.
Why did we choose NQO1 and in particular the NQO1
gene expression as a readout parameter for NRF2 pathway
activity and activation in kidney disease? Several lines of evi-
dence support our approach. First, NQO1 belongs to the con-
served NRF2 target genes, and in a recent integrated
transcriptomic and proteomic analysis of NRF2 function,
NQO1 was conﬁrmed as a robust marker for NRF2 activity
[2, 23]. Second, reduced expression of NQO1 was shown in
several kidney disease models, also in nonrenal cells, and
upregulation of NQO1 was repeatedly shown in NRF2-
dependent kidney protection, again including nonrenal cells
[4–8, 24]. Third, it has been shown that theNQO1 expression
is stimulated by the NRF2 activators CDDO (1-[2-cyano-
3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazolide), dh404
(2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid-9,11-dihy-
dro-triﬂuoroethyl amide), and bardoxolone methyl and that
this eﬀect is abrogated in NRF2−/− mice [5, 8, 23]. Notably,
bardoxolone methyl stimulates the NQO1 gene expression
also in PBMCs [3].
Some consideration should be given to the eﬀect size of
the NQO1 increase in our study. With respect to the gene
expression of NQO1, we conﬁrmed a 3-4-fold increase in
NQO1 mRNA in CKD 1–5 patients compared to healthy
control subjects using three diﬀerent housekeeping genes
for the relative quantiﬁcation. A 5.6-fold increase in NQO1
mRNA was reported to be present in PBMCs from cancer
patients after 3 weeks of treatment with bardoxolone methyl
[3]. In T cell-speciﬁc KEAP1-deﬁcient mice, T cells showed
an 8-fold relative change in NQO1 mRNA [7]. In a mouse
model of ischemia-reperfusion injury- (IRI-) induced kidney
damage, the maximal response of NQO1 mRNA to IRI was
an ~1.8-fold increase in wild-type mice and a 5-fold increase
in KEAP1-knockdown mice [8]. We therefore conclude that
the diﬀerence in NQO1 mRNA level that we observed in
our study is of relevant magnitude and points to an activation
of the NRF2 pathway in CKD patients per se.
On the protein level, the NQO1 protein content in CKD
1–5 patients was not signiﬁcantly increased to 1.1-fold com-
pared to that in control subjects in our study. Similarly, the
treatment of mice with bardoxolone methyl resulted in an
~1.3-fold increase in NQO1 protein level [23]. Treatment of
5/6 nephrectomy rats with dh404 resulted in an ~3.3-fold
increase in NQO1 protein in the colon [5]. However, the
increase in the NQO1 protein content that we observed in
CKD 1–5 needs further investigation.
Eﬀects on gene expression and protein content in
CKD are mediated by a multitude of mechanisms. The
observed increase in the NQO1 gene expression in our
study might be a response to NRF2-stimulating conditions
prevalent in patients with CKD, like oxidative stress or
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Figure 1: NQO1 gene expression. (a) Ampliﬁcation curves and melting curves for NQO1 in monocytes from a patient with CKD 4
(CKD, orange), a hemodialysis patient (CKD 5D, black), and a healthy subject (red). (b) Box and whisker plots (whiskers,
minimum to maximum) showing summary data of the NQO1 gene expression in healthy subjects (n = 16), CKD 1–5 patients (n = 29),
and CKD 5D patients (n = 34) normalized to ACTB, RPL41, and TBP. Comparison by Dunn’s posttest. ∗p < 0 05; ∗∗p < 0 01;
∗∗∗p < 0 001.
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lipopolysaccharide-induced inﬂammation [25, 26]. Patients
with coexisting CVD, which is also associated with oxida-
tive stress, might be especially aﬀected [27]. This is
supported by the higher CVD prevalence in CKD 1–5
patients with a higher NQO1 gene expression that we
observed. In addition, low concentrations of the uremic toxin
methylglyoxal were shown to increase the NQO1 mRNA
concentration [28].
We also observed that the increase in the NQO1 gene
expression in CKD 5D patients was less pronounced com-
pared to that in CKD 1–5 patients. This is in line with a
depressive eﬀect of high concentrations of uremic toxins on
the NRF2 pathway. This eﬀect might be more pronounced
in this patient group with advanced uremia. For example,
the uremic toxin indoxyl sulfate was shown to downregulate
NRF2 mRNA and NRF2 protein content [24].
The protein content of NQO1 appeared slightly upregu-
lated in CKD 1–5 patients and not upregulated in long-term
uremic CKD 5D patients. Such discrepancy between gene
expression and protein content was already demonstrated
by our group for another cytosolic antioxidant protein that
also is under the transcriptional regulation of an antioxidant
response element—superoxide dismutase type 1 [15].
Our study adds important information to the discussion
about the putative use ofNRF2 activators in CKD.NRF2 acti-
vators serve to upregulate the expression of NRF2 target
genes like NQO1. However, our study showed that the
NQO1 gene expression was already signiﬁcantly upregulated
in monocytes, which points to a relevant stimulation of the
NRF2 pathway in these cells in CKD patients. Therefore, as
the systemic application of NRF2 activators aﬀects diﬀerent
cell and tissue types, the NRF2 pathway in kidney disease
needs to be investigated in diﬀerent human cells and tissues.
This is of relevance as the overactivation of a potent tran-
scription factor like NRF2 was suggested as potentially dele-
terious for the cardiovascular system [27]. Therefore, a
preexisting activation of the NRF2 system in CKD patients
especially with CVD, as suggested by our results, could
be seen in line with the increased rate of cardiovascular
events in the BEACON trial [11]. Moreover, an additional
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Figure 2:NQO1 protein content. (a) To show the eﬀective detection ofNQO1 and ACTB protein by antibodies in the cell material used in our
study, we performed immunoblot analyses with cells obtained from healthy control subjects. Immunoblots ofNQO1 (expected size 26/27 kDa
and 31 kDa) and ACTB (expected size 42 kDa) in monocytes are shown. (b) Pseudocolored ﬂuorescence intensities of in-cell Western assays
for the quantiﬁcation of the NQO1 protein content relative to the ACTB protein content in monocytes from a healthy subject, a patient with
CKD, and a patient with CKD 5D. Measurements were always performed in triplicate. (c) Box and whisker plots (whiskers, minimum to
maximum) showing summary data of NQO1 protein in healthy subjects (n = 13), CKD 1–5 patients (n = 23), and CKD 5D patients
(n = 29) normalized to ACTB. p = 0 07 by Kruskal-Wallis test.
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depressive eﬀect of CKD on antioxidant enzymes, especially
in advanced uremic conditions, could reduce eﬀectiveness
of NRF2 activation.
Taken together, we showed a relevant upregulation in
gene expression of the NRF2 target NQO1 in patients with
CKD 1–5 together with a slight increase in the NQO1 protein
content in monocytes from these patients. Moreover, we
found that in more pronounced uremia (CKD 5D), the
NQO1 gene expression was less upregulated than that in
CKD 1–5 and NQO1 protein content was not increased.
We conclude that in CKD patients, NRF2 activation is
modulated through inﬂuence on both gene expression and
protein content of NRF2 targets in a complex way.
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